Global Acromegaly Market Size By Type (Somatostatin Analogues, Dopamine Agonists), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Acromegaly Market was valued at USD 1.45 billion in 2023 and is projected to reach USD 2.37 billion by 2031, expanding at a CAGR of 6.3% during the forecast period from 2023 to 2031. The growth is fueled by increasing awareness about rare endocrine disorders, improvements in diagnostic techniques, and a surge in targeted therapy approvals. Acromegaly is a rare hormonal disorder often caused by benign pituitary tumors leading to excess growth hormone (GH). Early diagnosis and availability of pharmacological therapies such as somatostatin analogs, growth hormone receptor antagonists, and dopamine agonists are significantly contributing to market expansion.

Drivers:

1. Rising Prevalence of Pituitary Tumors:

Improved diagnostic capabilities and broader healthcare coverage are leading to more frequent identification of acromegaly cases worldwide.

2. Advancements in Targeted Therapies:

The development of long-acting and more tolerable therapies is enhancing patient compliance, improving treatment outcomes, and driving demand.

3. Increased Awareness and Screening Programs:

Government and private sector initiatives to improve early detection are resulting in a growing patient pool entering treatment regimens.

Restraints:

1. High Treatment Costs:

The cost of lifelong therapies and monitoring can be prohibitive, especially in lower-income countries without insurance support.

2. Limited Access in Developing Regions:

Lack of awareness, infrastructure, and endocrinology specialists limits diagnosis and treatment in rural and underdeveloped areas.

Opportunity:

1. Expanding Clinical Pipeline:

Several biopharmaceutical companies are investing in R&D for improved formulations and novel treatment options, including oral and gene therapies.

2. Growth in Personalized Medicine:

As genomic profiling becomes more prevalent, personalized approaches to managing acromegaly are expected to open new market avenues.

Market by Treatment Type Insights:

In 2023, the Somatostatin Analogs segment led the market, owing to their high efficacy in controlling GH secretion and widespread physician preference as a first-line pharmacological option. The Growth Hormone Receptor Antagonists segment is projected to witness the highest CAGR, driven by their growing use in patients unresponsive to first-line treatments.

Market by End-use Insights:

Hospitals were the dominant end-use segment in 2023, accounting for over 60% of the market. The concentration of specialized endocrinology departments in hospitals ensures better diagnostic and therapeutic capabilities. Meanwhile, specialty clinics are anticipated to grow rapidly due to increasing outpatient visits for long-term monitoring and follow-ups.

Market by Regional Insights:

North America held the largest share of the global acromegaly market in 2023, supported by robust healthcare infrastructure, high awareness, and favorable reimbursement frameworks. Europe follows closely due to advanced diagnostic systems and established regulatory support for orphan drugs. The Asia-Pacific region is forecasted to register the fastest growth during the forecast period, driven by improvements in healthcare accessibility and increasing investment in rare disease diagnostics.

Competitive Scenario:

Key players in the Global Acromegaly Market include Pfizer Inc., Ipsen, Chiasma Inc. (acquired by Amryt Pharma), Crinetics Pharmaceuticals, Camurus AB, Novartis AG, and Strongbridge Biopharma. These companies focus on expanding treatment portfolios, regulatory approvals, and strategic collaborations to boost their presence. For example:

In 2024, Pfizer announced expanded Phase III trial results for a once-weekly somatostatin analog.

Amryt Pharma, post its acquisition of Chiasma, launched a patient support program for oral acromegaly therapy to enhance adherence.

Crinetics Pharmaceuticals progressed in clinical development of its novel oral GH antagonist (CRN00808), targeting improved compliance.

Scope of Work – Global Acromegaly Market

Key Market Developments:

July 2024: Ipsen received FDA priority review status for an extended-release version of lanreotide, aimed at reducing dosing frequency.

March 2024: Camurus secured EMA approval for its novel depot formulation of octreotide.

December 2023: Novartis partnered with a biotech start-up to co-develop a gene therapy-based solution for acromegaly treatment.

FAQs:

1. What is the current market size of the Global Acromegaly Market?

The Global Acromegaly Market was valued at USD 1.45 billion in 2023.

2. What is the major growth driver of the Global Acromegaly Market?

The market is primarily driven by the rising prevalence of pituitary tumors and advancements in targeted therapies.

3. Which is the largest region during the forecast period in the Global Acromegaly Market?

North America is expected to remain the dominant regional market through 2031.

4. Which segment accounted for the largest market share in the Global Acromegaly Market?

The Somatostatin Analogs segment accounted for the largest share in 2023.

5. Who are the key market players in the Global Acromegaly Market?

Key players include Pfizer Inc., Ipsen, Amryt Pharma (Chiasma), Crinetics Pharmaceuticals, Camurus AB, and Novartis AG.